DexCom, Inc. (DXCM)
Salud / Dispositivos médicos (monitoreo continuo de glucosa)
Leader in continuous glucose monitoring (CGM), with a still-underpenetrated addressable market (589 million diabetics worldwide, more than 25 million people with type 2 diabetes not on insulin in the U.S. alone, a segment Stelo is only beginning to reach) and expanding margins (GAAP operating margin from 13% to 23% over four years). At ~$91 (35× earnings), 5-year base ~$114 (+5%): Fairly valued.
- Price
- $90.65
- Intrinsic value (5y, base)
- $114
- Total annual return (5y)
- 4.7%
- Status (nominal)
- Fairly valued
- Margin of safety
- +1%
The essentials
- Leader in continuous glucose monitoring alongside Abbott: proprietary sensor technology, a patent portfolio with staggered expirations through 2044, and negotiated reimbursement with the eight largest U.S. private insurers plus Medicare/Medicaid in ~48 states — a real regulatory and commercial barrier for new entrants.
- Growth is decelerating but from a high level: TTM revenue +15.5%, FY2026 guidance recently raised to +11-13% (Jul-30-2026), with GAAP operating margin expanding from 13.4% (FY2022) to 22.9% (TTM) on operating leverage. Stelo (over-the-counter glucose sensor) and the G7 15 Day extend the addressable market beyond the historical base of insulin users.
- Structural risk to watch: Medicare competitive bidding (DMEPOS) begins setting prices from 2028, and the company itself expects Medicare reimbursement to decline from then on; plus an FDA warning letter (Mar-2026) over manufacturing issues, with no production restriction today.
Intrinsic value — two valuation methods
The methods disagree: one places the value today above the price ($91) and the other below.
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $91 trades close to its value discounted to today (~$91); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($114) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$57.
Thesis
The business
DexCom is the leader, alongside Abbott, in continuous glucose monitoring: proprietary sensor technology protected by a patent portfolio staggered through 2044, reimbursement negotiated with the major insurers and with Medicare/Medicaid, and a still-underpenetrated addressable market (589 million diabetics worldwide; more than 25 million people with type 2 diabetes not on insulin in the U.S. alone, the entry point for Stelo). GAAP operating margin has been expanding strongly, from 13.4% (FY2022) to 22.9% (TTM), on operating leverage.
The valuation
A high-growth medical device company is valued on P/E over net income, which gives the equity value directly. At ~$91 DexCom trades at 35× earnings. The base scenario anchors year 1 on the revenue guidance the company raised on Jul-30-2026 (+11-13%, midpoint +12.0%), consistent with non-GAAP operating margin guidance (~23.5-24%); from there the trajectory decelerates smoothly toward +9.0% by year 5, with GAAP operating margin expanding toward ~26%. Cash does not accumulate: the surplus is returned almost entirely via buybacks, so value per share is divided by projected shares (after the expected net reduction), not today's shares. That gives ~$114/share in five years → +5% total return (DexCom pays no dividend).
The margin of safety
It trades close to intrinsic value, far from the required margin of safety. Total return at market price is +5%. The verdict is Fairly valued: a quality business with a real technology and reimbursement moat, whose biggest risk is not today but in 2028, when Medicare competitive bidding begins to set the reimbursement price.
What to watch
The main disconfirmer is regulatory and reimbursement-related, not competitive in the classic sense: Medicare competitive bidding (DMEPOS) sets prices from 2028, and the magnitude of that pressure on margin is not yet clear. In parallel, watch the resolution of the March 2026 FDA warning letter (no production restriction today, but with the risk of escalating) and the pace of Stelo adoption among the population with type 2 diabetes not on insulin, which is the longest-horizon growth lever outside the traditional insulin-user base.
Educational / informational. Does not constitute investment advice.